Logo Logo

Publications by Schneeweiss, A.

Up a level
Export as [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date
Number of items: 16.

Journal article

Möbus, V.; Jackisch, C.; Luck, H. J.; du Bois, A.; Thomssen, C.; Kuhn, W.; Nitz, U.; Schneeweiss, A.; Huober, J.; Harbeck, N.; Minckwitz, G. von; Runnebaum, I. B.; Hinke, A.; Konecny, G. E.; Untch, M.; Kurbacher, C. (2018): Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial. In: Annals of Oncology, Vol. 29, No. 1: pp. 178-185

Yardley, D. A.; Coleman, R.; Conte, P.; Cortes, J.; Brufsky, A.; Shtivelband, M.; Young, R.; Bengala, C.; Ali, H.; Eakel, J.; Schneeweiss, A.; de la Cruz-Merino, L.; Wilks, S.; O'Shaughnessy, J.; Gluck, S.; Li, H.; Miller, J.; Barton, D.; Harbeck, N. (2018): nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial. In: Annals of Oncology, Vol. 29, No. 8: pp. 1763-1770

Jäger, B. A. S.; Neugebauer, J.; Andergassen, U.; Melcher, C.; Schochter, F.; Mouarrawy, D.; Ziemendorff, G.; Clemens, M.; Abel, E. v.; Heinrich, G.; Schüller, K.; Schneeweiss, A.; Fasching, P.; Beckmann, M. W.; Scholz, Ch.; Friedl, T. W. P.; Friese, K.; Pantel, K.; Fehm, T.; Janni, W.; Rack, B. (2017): The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trial.
In: PLOS One 12(6), e0173593 [PDF, 1MB]

Hein, A.; Rack, B.; Li, L.; Ekici, A. B.; Reis, A.; Lux, M. P.; Cunningham, J. M.; Rübner, M.; Fridley, B. L.; Schneeweiss, A.; Tesch, H.; Lichtenegger, W.; Fehm, T.; Heinrich, G.; Rezai, M.; Beckmann, M. W.; Janni, W.; Weinshilboum, R. M.; Wang, L.; Fasching, P. A.; Häberle, L. (2017): Genetic Breast Cancer Susceptibility Variants and Prognosis in the Prospectively Randomized SUCCESS A Study. In: Geburtshilfe und Frauenheilkunde, Vol. 77, No. 6: pp. 651-659

Mackelenberg, M. van; Denkert, C.; Nekljudova, V.; Karn, T.; Schem, C.; Marme, F.; Stickeler, E.; Jackisch, C.; Hanusch, C.; Huober, J.; Fasching, P.; Blohmer, J.-U.; Kummel, S.; Müller, V.; Schneeweiss, A.; Untch, M.; Minckwitz, G. von; Weber, K.; Loibl, S. (2017): Outcome after neoadjuvant chemotherapy in progesterone receptor negative breast cancer patients - A pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials. In: Cancer Research, Vol. 77

Polasik, A.; Schramm, A.; Friedl, T. W. P.; Rack, B.; Trapp, E.; Fasching, P. A.; Taran, F.-A.; Hartkopf, A.; Schneeweiss, A.; Müller, V.; Aktas, B.; Pantel, K.; Meier-Stiegen, F.; Wimberger, P.; Janni, W.; Fehm, T. (2017): DETECT III and IV - Individualized CTC-based therapy of metastatic breast cancer. In: Cancer Research, Vol. 77

Polasik, A.; Schramm, A.; Friedl, T. W. P.; Rack, B.; Trapp, E.; Tzschaschel, M.; Fasching, P. A.; Taran, F.-A.; Hartkopf, A.; Schneeweiss, A.; Müller, V.; Aktas, B.; Pantel, K.; Meier-Stiegen, F.; Wimberger, P.; Janni, W.; Fehm, T. (2017): The DETECT V-study - Comparison of dual HER2-targeted therapy with trastuzumab plus pertuzumab in combination with chemo-or endocrine therapy in patients with HER2-positive and hormone-receptor positive metastatic breast cancer. In: Cancer Research, Vol. 77

Tzschaschel, M. L. J.; Rack, B.; Majunke, L.; Trapp, E. K.; Mahner, S.; Fasching, P. A.; Fehm, T.; Schneeweiss, A.; Friedl, T. W. P.; Polasik, A.; Janni, W.; Alunni-Fabbroni, M. (2017): Profiling miRNA in high risk postoperative early breast cancer patients to detect possible association to correlation with immune system antitumor response. In: Cancer Research, Vol. 77

Tzschaschel, M. L. J.; Rack, B.; Andergassen, U.; Friedl, T. W. P.; Schneeweiss, A.; Müller, V.; Tanja, F.; Pantel, K.; Gade, J.; Lorenz, R.; Rezai, M.; Tesch, H.; Soeling, U.; Polasik, A.; Alunni-Fabbroni, M.; Trapp, E. K.; Mahner, S.; Schindlbeck, C.; Lichtenegger, W.; Beckmann, M. W.; Fasching, P. A.; Janni, W. (2017): Dynamics of circulating tumor cells during the course of chemotherapy and prognostic relevance across molecular subtypes in high-risk early breast cancer patients Results from the adjuvant SUCCESS A trial. In: Cancer Research, Vol. 77

Yardley, D.; Coleman, R.; Conte, P.; Cortes, J.; Brufsky, A.; Shtivelband, M.; Young, R.; Bengala, C.; Ali, H.; Eakel, J.; Schneeweiss, A.; Cruz Merino, L. de la; Wilks, S.; O'Shaugnessy, J.; Glück, S.; Li, H.; Beck, R.; Barton, D.; Harbeck, N. (2017): nab-paclitaxel plus carboplatin or gemcitabine vs gemcitabine/carboplatin as first-line treatment for patients with triple-negative metastatic breast cancer: Results from the randomized phase 2 portion of the tnAcity trial. In: Cancer Research, Vol. 77

Schramm, A.; Fried, T. W. P.; Huober, J.; Jäger, B.; Rack, B.; Trapp, E.; Fasching, P. A.; Taran, F.-A.; Hartkopf, A.; Schneeweiss, A.; Müller, V.; Aktas, B.; Pante, K.; Meier-Stiegen, F.; Wimberger, P.; Kümmel, S.; Gebauer, G.; Müller, L.; Janni, W.; Fehm, T. (2016): The DETECT study program - Personalized treatment in metastatic breast cancer based on circulating tumor cells. In: Cancer Research, Vol. 76

Janni, W.; Schramm, A.; Friedl, T. W. P.; Schochter, F.; Huober, J.; Rack, B.; Alunni-Fabbroni, M.; Fasching, P. A.; Taran, F.-A.; Hartkopf, A.; Schneeweiss, A.; Müller, V.; Aktas, B.; Krawczyk, N.; Pantel, K.; Fehm, T. (2016): Predictors for discordance in HER2 phenotype between primary tumor and circulating tumor cells in women with metastatic breast cancer. In: Cancer Research, Vol. 76

Benz, S. C.; Rabizadeh, S.; Cecchi, F.; Beckman, M. W.; Brucker, S. Y.; Hartmann, A.; Golovato, J.; Hembrough, T.; Janni, W.; Rack, B.; Sanborn, J. Z.; Schneeweiss, A.; Vaske, C. J.; Soon-Shiong, P.; Fasching, P. A. (2016): Integrating whole genome sequencing data with RNAseq, pathway analysis, and quantitative proteomics to determine prognosis after standard adjuvant treatment with trastuzumab and chemotherapy in primary breast cancer patients. In: Cancer Research, Vol. 76

Schröder, L.; Rack, B.; Sommer, H.; Koch, J. G.; Weissenbacher, T.; Janni, W.; Schneeweiss, A.; Rezai, M.; Lorenz, R.; Jäger, B.; Schramm, A.; Häberle, L.; Fasching, P. A.; Friedl, T. W. P.; Beckmann, M. W.; Scholz, C. (2016): Toxicity Assessment of a Phase III Study Evaluating FEC-Doc and FEC-Doc Combined with Gemcitabine as an Adjuvant Treatment for High-Risk Early Breast Cancer: the SUCCESS-A Trial. In: Geburtshilfe und Frauenheilkunde, Vol. 76, No. 5: pp. 542-550

Schramm, A.; Friedl, T.; Rack, B.; Trapp, E.; Fasching, P. A.; Taran, F.-A.; Hartkopf, A.; Schneeweiss, A.; Müller, V.; Aktas, B.; Pantel, K.; Meier-Stiegen, F.; Wimberger, P.; Kümmel, S.; Gebauer, G.; Müller, L.; Janni, W.; Fehm, T. (2016): The DETECT Study Concept - Metastatic breast cancer and circulating tumor cells. In: Oncology Research and Treatment, Vol. 39: pp. 46-47

Janni, W.; Schramm, A.; Friedl, T. W. P.; Schochter, E.; Huober, J.; Rack, B.; Alunni-Fabbroni, M.; Fasching, P. A.; Taran, F.-A.; Hortkopf, A.; Schneeweiss, A.; Mueller, V.; Aktas, B.; Krawczyk, N.; Pantel, K.; Fehm, T. (2016): Factors Predicting Discordance in HER2 Phenotype between Primary Tumor and Circulating Tumor Cells in Women with Metastatic Breast Cancer. In: Oncology Research and Treatment, Vol. 39: p. 47

This list was generated on Wed May 25 06:06:04 2022 CEST.